UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy

Lung cancer (Amsterdam, Netherlands), 2013-02, Vol.79 (2), p.167-172

2013

Volltextzugriff (PDF)

Nivolumab-refractory patients with advanced non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2019-04, Vol.130, p.128-134

2019

Volltextzugriff (PDF)

Echocardiographic features, mortality, and adrenal function in patients with cirrhosis and septic shock

Acta anaesthesiologica Scandinavica, 2008-01, Vol.52 (1), p.45-51

2008

Volltextzugriff (PDF)

Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021

ESMO open, 2024-02, Vol.9 (2), p.102240-102240, Article 102240

2024

Volltextzugriff (PDF)

Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort

Annals of oncology, 2018-10, Vol.29, p.viii406-viii406

2018

Volltextzugriff (PDF)

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

Respiratory medicine and research, 2020-11, Vol.78, p.100769-100769, Article 100769

2020

Volltextzugriff (PDF)

A mobile pulmonary mass

La revue de medecine interne, 2012-10, Vol.33 (10), p.595-596

2012

Volltextzugriff (PDF)

Rechallenge de l’immunothérapie dans les cancers bronchiques non à petites cellules de stade IV

Revue des maladies respiratoires actualités, 2022-05, Vol.14 (1), p.1S47-1S51

Giroux Leprieur, E.

2022

Volltextzugriff (PDF)

Infections virales chroniques (hépatites, VIH) et impact sur le choix thérapeutique

Revue des maladies respiratoires actualités, 2021-09, Vol.13 (2), p.2S272-2S279

Leprieur, E. Giroux

2021

Volltextzugriff (PDF)

Role of the Sonic Hedgehog pathway in thoracic cancers

Revue des maladies respiratoires, 2015-10, Vol.32 (8), p.800

2015

Volltextzugriff (PDF)

135P Soluble PD-L1 (sPD-L1) as a predictive biomarker in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) in the first-line setting

Annals of oncology, 2024-09, Vol.35, p.S269-S270

2024

Volltextzugriff (PDF)

Une masse pulmonaire mobile

La revue de medecine interne, 2012-10, Vol.33 (10), p.595-596

2012

Volltextzugriff (PDF)

Rechallenge de l'immunothérapie dans les cancers bronchiques non à petites cellules de stade IV

Revue des maladies respiratoires actualités, 2022-05, Vol.14 (1), p.1S47-1S51

Giroux Leprieur, Étienne

2022

Volltextzugriff (PDF)

1752P Clinical benefit of immunotherapies in advanced cancer in France: A population-based estimate from 2014 to 2021

Annals of oncology, 2023-10, Vol.34, p.S948-S948

2023

Volltextzugriff (PDF)

Infections virales chroniques (hépatites, VIH) et impact sur le choix thérapeutique

Revue des maladies respiratoires actualités, 2022-10, Vol.14 (2), p.2S351-2S357

2022

Volltextzugriff (PDF)

Non-small cell lung cancer: risk factors of radiation pneumonitis

Cancer radiothérapie, 2012-07, Vol.16 (4), p.257-262

2012

Volltextzugriff (PDF)

1499P Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer

Annals of oncology, 2023-10, Vol.34, p.S844-S844

2023

Volltextzugriff (PDF)

1496P Higher levels of CSF-1 support resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer

Annals of oncology, 2023-10, Vol.34, p.S843-S843

2023

Volltextzugriff (PDF)

1324P Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial

Annals of oncology, 2024-09, Vol.35, p.S842-S842

2024

Volltextzugriff (PDF)

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

The lancet respiratory medicine, 2018-10, Vol.6 (10), p.771-781

2018

Volltextzugriff (PDF)

1262MO Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely resected non-small cell lung cancer (NSCLC) in phase III IFCT-0302 trial

Annals of oncology, 2023-10, Vol.34, p.S732-S732

2023

Volltextzugriff (PDF)

1498P HGF/MET pathway is associated with poor efficacy of Immune checkpoint inhibitors (ICIs) in advanced-stage NSCLC

Annals of oncology, 2023-10, Vol.34, p.S844-S844

2023

Volltextzugriff (PDF)

Épidémiologie des cancers du poumon en France : les tendances actuelles

Revue des maladies respiratoires actualités, 2020-10, Vol.12 (2), p.2S6-2S13

2020

Volltextzugriff (PDF)

1330P Discontinuation of ICIs above 18 months of treatment in real-life patients with NSCLC: A multicentric retrospective study

Annals of oncology, 2020-09, Vol.31, p.S857-S857

2020

Volltextzugriff (PDF)

Rôle de la voie HGF/cMET dans la résistance aux inhibiteurs de point de contrôle immunitaire dans le cancer bronchique non à petites cellules

Revue des maladies respiratoires, 2023-02, Vol.40 (2), p.120-120

2023

Volltextzugriff (PDF)

1 – 25 von 126

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(126)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(20)
Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Female
(11)
Life Sciences
(11)
Non-Small Cell Lung Cancer
(11)
Respiratory System
(11)
Middle Aged
(10)
Aged
(9)
Cancer Bronchique Non À Petites Cellules
(9)
Male
(8)
Cancer
(7)
Lung Neoplasms - Drug Therapy
(7)
Oncology
(7)
Sciences Biologiques Et Medicales
(7)
Sciences Medicales
(7)
Adult
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(6)
Chemotherapy
(6)
Lung Cancer
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy

Nivolumab-refractory patients with advanced non-small-cell lung cancer

Echocardiographic features, mortality, and adrenal function in patients with cirrhosis and septic shock

Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021

Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

A mobile pulmonary mass

Rechallenge de l’immunothérapie dans les cancers bronchiques non à petites cellules de stade IV

Infections virales chroniques (hépatites, VIH) et impact sur le choix thérapeutique

Role of the Sonic Hedgehog pathway in thoracic cancers

135P Soluble PD-L1 (sPD-L1) as a predictive biomarker in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) in the first-line setting

Une masse pulmonaire mobile

Rechallenge de l'immunothérapie dans les cancers bronchiques non à petites cellules de stade IV

1752P Clinical benefit of immunotherapies in advanced cancer in France: A population-based estimate from 2014 to 2021

Infections virales chroniques (hépatites, VIH) et impact sur le choix thérapeutique

Non-small cell lung cancer: risk factors of radiation pneumonitis

1499P Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer

1496P Higher levels of CSF-1 support resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer

1324P Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

1262MO Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely resected non-small cell lung cancer (NSCLC) in phase III IFCT-0302 trial

1498P HGF/MET pathway is associated with poor efficacy of Immune checkpoint inhibitors (ICIs) in advanced-stage NSCLC

Épidémiologie des cancers du poumon en France : les tendances actuelles

1330P Discontinuation of ICIs above 18 months of treatment in real-life patients with NSCLC: A multicentric retrospective study

Rôle de la voie HGF/cMET dans la résistance aux inhibiteurs de point de contrôle immunitaire dans le cancer bronchique non à petites cellules

Suchergebnisse filtern